West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials - PubMed There were a substantial number of men whose risk of a coronary event was more than 10% at 5 years in the WOSCOPS cohort. The absolute benefit of pravastatin treatment of hyperlipidaemia is less in th...

We also compared #WOSCOPS findings with those of the Scandinavian Simvastatin Survival Study (4S) and the Medical Research Council (MRC) trial of treatment for mild to moderate hypertension in middle-aged men.

pubmed.ncbi.nlm.nih.gov/8918276/

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study - PubMed The West of Scotland Coronary Prevention Study (WOSCOPS) is a randomized, double-blind, placebo-controlled trial of pravastatin in a primary prevention context. The primary end point of the trial is d...

#WOSCOPS recruits are, on average, 7 to 9 years older than subjects in other trials and have average total cholesterol levels 0.5 mmol/L (19.4 mg/dl) lower than those in the #Helsinki Heart Study and the Lipid Research Clinics-Coronary Primary Prevention Trial.

pubmed.ncbi.nlm.nih.gov/7653449/

High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease - PubMed Troponin concentration predicts coronary events, is reduced by statin therapy, and change at 1 year is associated with future coronary risk independent of cholesterol lowering. Serial troponin measure...

Troponin concentration predicts coronary events, is reduced by statin therapy, and change at 1 year is associated with future coronary risk independent of cholesterol lowering.
#WOSCOPS
pubmed.ncbi.nlm.nih.gov/28007133/

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above:... The present analyses provide robust novel evidence for the short- and long-term benefits of lowering LDL-C for the primary prevention of cardiovascular disease among individuals with primary elevation...

#WOSCOPS enrolled 6595 men aged 45 to 64 years, who were randomly assigned to pravastatin 40 mg/d or placebo.

pubmed.ncbi.nlm.nih.gov/28877913/

18% benefit in mortality over 20 years. Significant.

Raised baseline LDLc benefited slightly more.

#WOSCOPS randomised people to statins for 5 years and then followed up for 20 years.

If the statins were so beneficial, why did they not ensure all participants were started on statins?

Are we supposed to only prescribe for 5 years?

Five years treatment of 1000 patients with pravastatin (40 mg/day) saved the NHS £710 000 (P < 0.001), including the cost of pravastatin and lipid and safety monitoring, and gained 136 QALYs (P = 0.017) over the 15-year period
#WOSCOPS
pubmed.ncbi.nlm.nih.gov/23839541/

Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting - PubMed URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00738725 (BioImage) and NCT00005130 (CARDIA). WOSCOPS was carried out and completed before the requirement for clinical trial registration.

#WOSCOPS [West of Scotland Coronary Prevention Study]; n=4910) and 2 observational cohort studies ( #CARDIA [Coronary Artery Risk Development in Young Adults] and BioImage.

There is a genetic subgroup with higher risk of MACE and who benefit sig more from statins.
pubmed.ncbi.nlm.nih.gov/28223407/